<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35402070</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2162-2531</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>28</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>14</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular therapy. Nucleic acids</Title>
          <ISOAbbreviation>Mol Ther Nucleic Acids</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Aptamer Ob2, a novel AChE inhibitor, restores cognitive deficits and alleviates amyloidogenesis in 5×FAD transgenic mice.</ArticleTitle>
        <Pagination>
          <StartPage>114</StartPage>
          <EndPage>123</EndPage>
          <MedlinePgn>114-123</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.omtn.2022.02.018</ELocationID>
        <Abstract>
          <AbstractText>Loss of cerebral cholinergic neurons and decreased levels of acetylcholine (ACh) are considered to be major factors causing cognitive dysfunction in Alzheimer's disease (AD). Abnormally elevated levels of acetylcholinesterase (AChE) resulting in decreased levels of ACh are common in AD patients; thus, AChE inhibitors (AChEIs) are widely used for the treatment of AD. In our previous work, we acquired DNA aptamers Ob1, Ob2, and Ob3 against human brain AChE from systematic evolution of ligands by exponential enrichment (SELEX). In this study, we investigated the effect of these aptamers on learning and memory abilities, as well as the underlying mechanism in a 5×FAD transgenic AD mouse model. Here, we showed that only aptamer Ob2 exhibits a good inhibitory effect on both mouse and human AChE activity. In addition, chronic treatment with aptamer Ob2 significantly improved cognitive ability of 5×FAD mice in the Morris water maze. Moreover, the mechanism of aptamer Ob2 in 5×FAD mice may be associated with its inhibition of AChE activity, alleviation of the levels of Aβ by lowering the expression of β-secretase (BACE1), and activation of astrocytes in the brains of 5×FAD mice. These results indicate that aptamer Ob2 exhibits potential as an effective AChEI for the treatment of AD.</AbstractText>
          <CopyrightInformation>© 2022 The Authors.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Zhiman</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Mental Health of the Ministry of Education, Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangdong Province Key Laboratory of Psychiatric Disorders, Department of Neurobiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou 510900, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Mental Health of the Ministry of Education, Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangdong Province Key Laboratory of Psychiatric Disorders, Department of Neurobiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Xiaoting</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Hongjie</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>The First Affiliated Hospital, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yajun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>The First Affiliated Hospital, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Mingliang</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Xinxin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Mental Health of the Ministry of Education, Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangdong Province Key Laboratory of Psychiatric Disorders, Department of Neurobiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Yingying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Mental Health of the Ministry of Education, Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangdong Province Key Laboratory of Psychiatric Disorders, Department of Neurobiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Ting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Mental Health of the Ministry of Education, Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangdong Province Key Laboratory of Psychiatric Disorders, Department of Neurobiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Yusheng</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai 519000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xingmei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Mental Health of the Ministry of Education, Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangdong Province Key Laboratory of Psychiatric Disorders, Department of Neurobiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Ther Nucleic Acids</MedlineTA>
        <NlmUniqueID>101581621</NlmUniqueID>
        <ISSNLinking>2162-2531</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">5×FAD mice</Keyword>
        <Keyword MajorTopicYN="N">AChE inhibitor</Keyword>
        <Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword>
        <Keyword MajorTopicYN="N">MT: Oligonucleotides: Therapies and Applications</Keyword>
        <Keyword MajorTopicYN="N">acetylcholinesterase</Keyword>
        <Keyword MajorTopicYN="N">aptamer</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>11</Day>
          <Hour>5</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35402070</ArticleId>
        <ArticleId IdType="pmc">PMC8938253</ArticleId>
        <ArticleId IdType="doi">10.1016/j.omtn.2022.02.018</ArticleId>
        <ArticleId IdType="pii">S2162-2531(22)00046-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Patterson C.  Alzheimer’s Disease International; London: 2018. World Alzheimer Report 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Jagust W. Imaging the evolution and pathophysiology of Alzheimer disease. Nat. Rev. Neurosci. 2018;19:687–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7032048</ArticleId>
            <ArticleId IdType="pubmed">30266970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reiss A.B., Arain H.A., Stecker M.M., Siegart N.M., Kasselman L.J. Amyloid toxicity in Alzheimer’s disease. Rev. Neurosci. 2018;29:613–627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29447116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naseri N.N., Wang H., Guo J., Sharma M., Luo W. The complexity of tau in Alzheimer’s disease. Neurosci. Lett. 2019;705:183–194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7060758</ArticleId>
            <ArticleId IdType="pubmed">31028844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breijyeh Z., Karaman R. Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules. 2020;25:5789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7764106</ArticleId>
            <ArticleId IdType="pubmed">33302541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calsolaro V., Edison P. Neuroinflammation in Alzheimer’s disease: current evidence and future directions. Alzheimers Dement. 2016;12:719–732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27179961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stanciu G.D., Luca A., Rusu R.N., Bild V., Beschea Chiriac S.I., Solcan C., Bild W., Ababei D.C. Alzheimer’s disease pharmacotherapy in relation to cholinergic system involvement. Biomolecules. 2019;10:40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7022522</ArticleId>
            <ArticleId IdType="pubmed">31888102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haam J., Yakel J.L. Cholinergic modulation of the hippocampal region and memory function. J. Neurochem. 2017;142:111–121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5645066</ArticleId>
            <ArticleId IdType="pubmed">28791706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hampel H., Mesulam M.M., Cuello A.C., Farlow M.R., Giacobini E., Grossberg G.T., Khachaturian A.S., Vergallo A., Cavedo E., Snyder P.J., et al.  The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain. 2018;141:1917–1933.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6022632</ArticleId>
            <ArticleId IdType="pubmed">29850777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferreira-Vieira T.H., Guimaraes I.M., Silva F.R., Ribeiro F.M. Alzheimer's disease: targeting the cholinergic system. Curr. Neuropharmacol. 2016;14:101–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4787279</ArticleId>
            <ArticleId IdType="pubmed">26813123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lazarevic-Pasti T., Leskovac A., Momic T., Petrovic S., Vasic V. Modulators of acetylcholinesterase activity: from Alzheimer's disease to anti-cancer drugs. Curr. Med. Chem. 2017;24:3283–3309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28685687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H., Zhang H. Reconsideration of anticholinesterase therapeutic strategies against Alzheimer’s disease. ACS Chem. Neurosci. 2018;10:852–862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30521323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed T., Zahid S., Mahboob A., Mehpara Farhat M. Cholinergic system and post-translational modifications: an insight on the role in alzheimer's disease. Curr. Neuropharmacol. 2017;15:480–494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5543671</ArticleId>
            <ArticleId IdType="pubmed">27012953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y., Lai B.S., Juhas M. Recent advances in aptamer discovery and applications. Molecules. 2019;24:941.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6429292</ArticleId>
            <ArticleId IdType="pubmed">30866536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ni S., Zhuo Z., Pan Y., Yu Y., Li F., Liu J., Wang L., Wu X., Li D., Wan Y., et al.  Recent progress in aptamer discoveries and modifications for therapeutic applications. ACS Appl. Mater. Inter. 2020;13:9500–9519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32603135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu G., Chen X. Aptamer-based targeted therapy. Adv. Drug Deliv. Rev. 2018;134:65–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6239901</ArticleId>
            <ArticleId IdType="pubmed">30125604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morita Y., Leslie M., Kameyama H., Volk D.E., Tanaka T. Aptamer therapeutics in cancer: current and future. Cancers. 2018;10:80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5876655</ArticleId>
            <ArticleId IdType="pubmed">29562664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan J., Xiong H., Cai S., Wen N., He Q., Liu Y., Peng D., Liu Z. Advances in aptamer screening technologies. Talanta. 2019;200:124–144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31036165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T., Chen C., Larcher L.M., Barrero R.A., Veedu R.N. Three decades of nucleic acid aptamer technologies: lessons learned, progress and opportunities on aptamer development. Biotechnol. Adv. 2019;37:28–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30408510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han J., Gao L., Wang J., Wang J. Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy. J. Cancer. 2020;11:6902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7592013</ArticleId>
            <ArticleId IdType="pubmed">33123281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filippi L., Bagni O., Nervi C. Aptamer-based technology for radionuclide targeted imaging and therapy: a promising weapon against cancer. Expert Rev. Med. Dev. 2020;17:751–758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32669004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nimjee S.M., White R.R., Becker R.C., Sullenger B.A. Aptamers as therapeutics. Annu. Rev. Pharmacol. Toxicol. 2017;57:61–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6035745</ArticleId>
            <ArticleId IdType="pubmed">28061688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X.M., Li Q., Shi Y.S., Wu J.H., Shao N.S., Liu G., Sun M.J. Specific oligobodies against human brain acetylcholinesterase. Brain Res. 2003;989:147–151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14556936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y., Shi G.W., Liang Z.M., Sheng S.Y., Peng L., Wang Y.P., Wang F., Zhang X.M. Resveratrol improves cognition and decreases amyloid plaque formation in Tg6799 mice. Mol. Med. Rep. 2019;19:3783–3790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30864708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panek D., Wichur T., Godyń J., Pasieka A., Malawska B. Advances toward multifunctional cholinesterase and β-amyloid aggregation inhibitors. Future Med. Chem. 2017;9:1835–1854.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28925729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selkoe D.J., Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol. Med. 2016;8:595–608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4888851</ArticleId>
            <ArticleId IdType="pubmed">27025652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo T., Zhang D., Zeng Y., Huang T.Y., Xu H., Zhao Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Mol. Neurodegener. 2020;15:1–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7364557</ArticleId>
            <ArticleId IdType="pubmed">32677986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long J.M., Holtzman D.M. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179:312–339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6778042</ArticleId>
            <ArticleId IdType="pubmed">31564456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koelsch G. BACE1 function and inhibition: implications of intervention in the amyloid pathway of Alzheimer’s disease pathology. Molecules. 2017;22:1723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6151801</ArticleId>
            <ArticleId IdType="pubmed">29027981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uddin M.S., Kabir M.T., Tewari D., Mamun A.A., Mathew B., Aleya L., Barreto G.E., Bin-Jumah M.N., Abdel-Daim M.M., Ashraf G.M. Revisiting the role of brain and peripheral Aβ in the pathogenesis of Alzheimer's disease. J. Neurol. Sci. 2020;416:116974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32559516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Price B.R., Johnson L.A., Norris C.M. Reactive astrocytes: the nexus of pathological and clinical hallmarks of Alzheimer’s disease. Ageing Res. Rev. 2021;68:101335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8168445</ArticleId>
            <ArticleId IdType="pubmed">33812051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y., Wang X., Wang T., Hu X., Hui X., Yan M., Gao Q., Chen T., Li J., Yao M., et al.  Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization. Hepatology. 2011;53:493–503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21274871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han S.H., Park J.C., Byun M.S., Yi Da., Lee J.H., Mook-Jung I., KBASE Research Group  Blood acetylcholinesterase level is a potential biomarker for the early detection of cerebral amyloid deposition in cognitively normal individuals. Neurobiol. Aging. 2019;73:21–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30316049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson R.D., Van Mieghem T., Langlois S., Church P. Guideline no. 410: prevention, screening, diagnosis, and pregnancy management for fetal neural tube defects. J. Obstet. Gynaecol. Can. 2021;43:124–139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33212246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cummings J.L., Tong G., Ballard C. Treatment combinations for Alzheimer’s disease: current and future pharmacotherapy options. J. Alzheimers Dis. 2019;67:779–794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6398562</ArticleId>
            <ArticleId IdType="pubmed">30689575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q., He S., Chen Y., Feng F., Qu W., Sun H. Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer’s disease. Eur. J. Med. Chem. 2018;158:463–477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30243151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Macdonald J., Henri J., Goodman L., Xiang D., Duan W., Shigdar S. Development of a bifunctional aptamer targeting the transferrin receptor and epithelial cell adhesion molecule (EpCAM) for the treatment of brain cancer metastases. ACS Chem. Neurosci. 2017;8:777–784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28010059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X., Yang Y., Zhao H., Zhu T., Yang Z., Xu H., Fu Y., Lin F., Pan X., Li L., et al.  Enhanced in vivo blood–brain barrier penetration by circular tau-transferrin receptor bifunctional aptamer for tauopathy therapy. J. Am. Chem. Soc. 2020;142:3862–3872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31991082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren X., Zhao Y., Xue F., Zheng Y., Huang H., Wang W., Chang Y., Yang H., Zhang J. Exosomal DNA aptamer targeting α-synuclein aggregates reduced neuropathological deficits in a mouse Parkinson’s disease model. Mol. Ther. Nucleic Acids. 2019;17:726–740.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6709346</ArticleId>
            <ArticleId IdType="pubmed">31437653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ellman G.L., Courtney K.D., Andres V., Jr., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961;7:88–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13726518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang Z.M., Peng Y.H., Chen Y., Long L.L., Luo H.J., Chen Y.J., Liang Y.L., Tian Y.H., Li S.J., Shi Y.S., et al.  The BACE1-specific DNA aptamer A1 rescues amyloid-β pathology and behavioral deficits in a mouse model of Alzheimer’s disease. Nucleic Acid Ther. 2019;29:359–366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31513457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gould T.D., Dao D.T., Kovacsics C.E. The open field test. Neuromethods. 2010;83:1–20.</Citation>
        </Reference>
        <Reference>
          <Citation>Vorhees C.V., Williams M.T. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 2006;1:848–858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2895266</ArticleId>
            <ArticleId IdType="pubmed">17406317</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
